Travere Therapeutics (TVTX) said late Thursday the US Food and Drug Administration accepted its supplemental New Drug Application for approval of Filspari to treat focal segmental glomerulosclerosis, a kidney disease.
The drug application submission was based on phase 2 and phase 3 trial results involving both adult and pediatric patients, according to the company.
The FDA assigned a Prescription Drug User Fee Act target action date of Jan. 13, 2026, and signaled it is planning an advisory committee meeting regarding the application, the company added.
Shares of Travere Therapeutics were down 23% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。